Compass Therapeutics (CMPX) Leases (2023 - 2025)
Compass Therapeutics (CMPX) has disclosed Leases for 3 consecutive years, with $9.1 million as the latest value for Q4 2025.
- Quarterly Leases rose 35.18% to $9.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.1 million through Dec 2025, up 35.18% year-over-year, with the annual reading at $9.1 million for FY2025, 35.18% up from the prior year.
- Leases hit $9.1 million in Q4 2025 for Compass Therapeutics, down from $9.5 million in the prior quarter.
- In the past five years, Leases ranged from a high of $9.8 million in Q2 2025 to a low of $1.2 million in Q2 2024.
- Historically, Leases has averaged $5.0 million across 3 years, with a median of $4.6 million in 2023.
- Biggest five-year swings in Leases: crashed 51.66% in 2024 and later surged 750.3% in 2025.
- Year by year, Leases stood at $1.8 million in 2023, then soared by 279.0% to $6.7 million in 2024, then skyrocketed by 35.18% to $9.1 million in 2025.
- Business Quant data shows Leases for CMPX at $9.1 million in Q4 2025, $9.5 million in Q3 2025, and $9.8 million in Q2 2025.